Blood Cancer Journal (Apr 2024)
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
- Thomas Lund,
- Michael Tveden Gundesen,
- Annette Juul Vangsted,
- Carsten Helleberg,
- Einar Haukås,
- Trine Silkjær,
- Jon Thor Asmussen,
- Elena Manuela Teodorescu,
- Bo Amdi Jensen,
- Tobias Schmidt Slørdahl,
- Hareth Nahi,
- Anders Waage,
- Niels Abildgaard,
- Fredrik Schjesvold,
- Nordic Myeloma Study Group
Affiliations
- Thomas Lund
- Department of Hematology, Odense University Hospital
- Michael Tveden Gundesen
- Department of Hematology, Odense University Hospital
- Annette Juul Vangsted
- Department of Hematology, Rigshospitalet
- Carsten Helleberg
- Department of Hematology, Rigshospitalet
- Einar Haukås
- Department of Blood and Cancer Diseases, Stavanger University Hospital
- Trine Silkjær
- Department of Hematology, Aarhus University Hospital
- Jon Thor Asmussen
- Department of Radiology, Odense University Hospital
- Elena Manuela Teodorescu
- Department of Hematology, Aalborg University Hospital
- Bo Amdi Jensen
- Department of Hematology, Zealand University Hospital
- Tobias Schmidt Slørdahl
- Department of Hematology, St. Olavs Hospital and Norwegian University of Science and Technology (NTNU)
- Hareth Nahi
- Karolinska Institutet
- Anders Waage
- Department of Hematology, St. Olavs Hospital and Norwegian University of Science and Technology (NTNU)
- Niels Abildgaard
- Department of Hematology, Odense University Hospital
- Fredrik Schjesvold
- Oslo Myeloma Center, Department of Hematology, Oslo University Hospital
- Nordic Myeloma Study Group
- DOI
- https://doi.org/10.1038/s41408-024-01046-2
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 5
Abstract
No abstracts available.
